Clinical Timeline Guide

GLP-1 Weight Loss Timeline: Month-by-Month Results

Based on real clinical trial data from STEP and SURMOUNT trials. See what to expect on semaglutide and tirzepatide week by week.

Written by GLP1Authority Editorial Team · Medically fact-checked
Last updated March 2026 · Read our methodology

Quick Answer: Most people lose 3-5% body weight in month 1, 10-15% by 6 months, and 15-20%+ by 12 months on semaglutide (based on STEP trials). Tirzepatide produces higher results: 20-21% by 12 months (SURMOUNT trials). Results vary significantly by starting weight, dose titration, diet, exercise, and individual metabolism.

How Fast Do GLP-1 Medications Work?

GLP-1 receptor agonists work remarkably fast compared to traditional weight loss approaches. Most patients experience appetite suppression within days, measurable weight loss within weeks, and significant body composition changes within months.

The clinical evidence comes from rigorous FDA-approval trials: the STEP 1-4 trials for semaglutide (Ozempic, Wegovy) and the SURMOUNT trials for tirzepatide (Mounjaro, Zepbound). These trials tracked thousands of patients over 68+ weeks and documented weight loss progression at each time point.

Month-by-Month Weight Loss Breakdown

📅 Month 1

Appetite Suppression Phase

3-5% Loss

Appetite suppression begins within days to 1 week. Gastrointestinal side effects peak and often improve by week 3-4. Sleep may improve despite appetite changes. Energy levels vary — some feel better, others experience fatigue initially.

📅 Months 2-3

Stabilization & Acceleration

8-12% Loss

By month 2, most patients have adapted to side effects. Weekly weight loss becomes more consistent (0.5-2 lbs per week typical). Side effects have usually resolved or become manageable. Patients often report improved food choices without conscious restriction.

📅 Months 4-6

Peak Loss Period

10-15% Loss

Months 4-6 represent the steepest weight loss period. Weight loss continues at 1-2 lbs per week. Body composition changes become visually apparent. Clothes fit differently; many need to downsize.

📅 Months 7-12

Plateau Begins

15-20% Loss

By month 7, many patients experience weight loss plateau — a normal physiological response. Weekly weight loss slows to 0.3-0.8 lbs per week. Appetite suppression may weaken slightly. Portion control becomes more important.

📅 Beyond 12 Months

Maintenance Phase

15-22% Loss

After 12 months, weight loss typically plateaus. The medication's primary benefit shifts from active loss to prevention of regain. Continued medication is necessary to maintain results.

Semaglutide vs. Tirzepatide: Clinical Results Comparison

Both medications are GLP-1 receptor agonists, but tirzepatide (Mounjaro, Zepbound) is a dual GLP-1/GIP receptor agonist, which may explain superior weight loss results in head-to-head trials.

Metric	Semaglutide (STEP Trials)	Tirzepatide (SURMOUNT Trials)
Week 12 Loss	3-5% (0.4 mg dose)	4-6% (2.4 mg dose)
Month 6 Loss	10-12%	12-15%
Week 68 (16 months) Loss	15-17% (2.4 mg dose)	20-21% (15 mg dose)
Maximum Dose	2.4 mg weekly	15 mg weekly
Titration Period	16 weeks (0.25 mg increments)	16 weeks (2.5 mg increments)
Side Effect Profile	Gastrointestinal (common but mild)	Gastrointestinal (slightly higher incidence)

Note: These are average results. Individual outcomes vary significantly. Data from FDA-published clinical trial results and peer-reviewed literature.